Enveric Biosciences, Inc. (ENVB) shareholders
ENVBNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.51−0.01 (-0.33%)
Close on Nov 13, 2026Market cap $6.78MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
11.8%
1M of 4M shares
Institutional holders
24
14 new, 1 sold out
Net institutional buying
0M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Waqas Khatri Joint filing with Ayrton Capital LLC (9.99%), Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B (9.99%) | 658,465 | 9.99% | 13G (passive) | Sep 30, 2025 |
| Steven Boyd Joint filing with Armistice Capital, LLC (9.99%) | 405,092 | 9.99% | 13G (passive) | Jun 30, 2026 |
| Sio Capital Management, LLC | 330,000 | 7.37% | 13G (passive) | Sep 30, 2026 |
| Orca Capital AG | 166,667 | 8.70% | 13G (passive) | Jan 30, 2025 |
| Lind Global Partners III LLC Joint filing with Lind Global Fund III LP (9.99%), Easton Jeff (9.99%) | 141,265 | 9.99% | 13G (passive) | Jan 28, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of ENVB | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Sio Capital Management, LLC | 180,000 | 4.02% | $248.40K | New | 0.04% |
| Ikarian Capital, LLC | 100,002 | 2.23% | $138.00K | New | 0.01% |
| AdvisorShares Investments LLC | 35,417 | 0.79% | $48.88K | +18,443 | 0.01% |
| Renaissance Technologies LLC | 32,058 | 0.72% | $44.24K | New | 0.00% |
| Armistice Capital, LLC | 32,000 | 0.71% | $44.16K | New | 0.00% |
| Boothbay Fund Management, LLC | 30,142 | 0.67% | $41.60K | New | 0.00% |
| XTX Topco Ltd | 18,990 | 0.42% | $26.21K | New | 0.00% |
| Hrt Financial LP | 15,458 | 0.35% | $21.00K | New | 0.00% |
| Vanguard Capital Management LLC | 14,912 | 0.33% | $20.58K | New | 0.00% |
| Citadel Advisors LLC | 13,965 | 0.31% | $19.27K | New | 0.00% |
| StoneX Group Inc. | 11,814 | 0.26% | $21.88K | New | 0.00% |
| Geode Capital Management, LLC | 11,794 | 0.26% | $16.27K | −20,355 | 0.00% |
| Morgan Stanley | 10,733 | 0.24% | $14.81K | New | 0.00% |
| Virtu Financial LLC | 10,690 | 0.24% | $15.00K | New | 0.00% |
| Tower Research Capital LLC (TRC) | 4,984 | 0.11% | $6.88K | +3,881 | 0.00% |
| SBI Securities Co., Ltd. | 2,676 | 0.06% | $3.69K | +2,593 | 0.00% |
| Jones Financial Companies Lllp | 1,000 | 0.02% | $1.42K | – | 0.00% |
| Integrated Wealth Concepts LLC | 702 | 0.02% | $969 | New | 0.00% |
| UBS Group AG | 201 | 0.00% | $277 | −3,411 | 0.00% |
| BlackRock, Inc. | 51 | 0.00% | $70 | – | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 24 | 1M | 11.8% | 14 / 3 | 2 / 1 | 0M | 0M |
| Q1 2026 | 11 | 0M | 1.2% | 2 / 2 | 1 / 2 | 0M | 0M |
| Q4 2025 | 11 | 0M | 0.5% | 11 / 0 | 0 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
4 funds held ENVB in Q2 2026, 80% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of ENVB | Value | % of fund | As of |
|---|---|---|---|---|---|
| AdvisorShares Psychedelics ETF | 35,417 | 0.79% | $48.88K | 0.11% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 14,912 | 0.33% | $20.58K | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 11,555 | 0.26% | $26.58K | 0.00% | May 31, 2026 |
| Fidelity Nasdaq Composite Index Fund | 911 | 0.02% | $2.10K | 0.00% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Joseph Edward Tucker | Chief Executive Officer, Director | 962,562 | 21.51% | Jun 3, 2026 |
| Kevin Michael Coveney | Chief Financial Officer | 180,746 | 4.04% | Jun 3, 2026 |
| Peter J. Facchini | Chief Innovation Officer | 559,357 | 12.50% | Jun 3, 2026 |
| Michael D. Webb | Director | 26,416 | 0.59% | Jun 3, 2026 |
| Frank Pasqualone | Director | 26,423 | 0.59% | Jun 3, 2026 |
| Sheila DeWitt | Director | 26,306 | 0.59% | Jun 3, 2026 |
| Marcus Schabacker | Director | 26,418 | 0.59% | Jun 3, 2026 |
| George A. Kegler | Director | 26,418 | 0.59% | Jun 3, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| George A. Kegler Director | Jun 1, 2026 | Award | +18,518 | – | – | 26,418 |
| Peter J. Facchini Chief Innovation Officer | Jun 1, 2026 | Award | +25,000 | – | – | 27,755 |
| Kevin Michael Coveney Chief Financial Officer | Jun 1, 2026 | Award | +133,333 | – | – | 180,746 |
| Michael D. Webb Director | Jun 1, 2026 | Award | +18,518 | – | – | 26,416 |
| Joseph Edward Tucker Chief Executive Officer, Director | Jun 1, 2026 | Award | +201,124 | – | – | 271,479 |
| Sheila DeWitt Director | Jun 1, 2026 | Award | +18,518 | – | – | 26,306 |
| Marcus Schabacker Director | Jun 1, 2026 | Award | +18,518 | – | – | 26,418 |
| Frank Pasqualone Director | Jun 1, 2026 | Award | +18,518 | – | – | 26,423 |
| Joseph Edward Tucker Chief Executive Officer, Director | Dec 23, 2025 | Award | +60,296 | – | – | 70,355 |
| Kevin Michael Coveney Chief Financial Officer | Dec 23, 2025 | Award | +40,198 | – | – | 47,413 |
| Michael D. Webb Director | Dec 23, 2025 | Award | +7,633 | – | – | 7,898 |
| Frank Pasqualone Director | Dec 23, 2025 | Award | +7,633 | – | – | 7,904 |
| George A. Kegler Director | Dec 23, 2025 | Award | +7,633 | – | – | 7,900 |
| Sheila DeWitt Director | Dec 23, 2025 | Award | +7,633 | – | – | 7,788 |
| Marcus Schabacker Director | Dec 23, 2025 | Award | +7,633 | – | – | 7,900 |
| Joseph Edward Tucker CHIEF EXECUTIVE OFFICER, Director | May 8, 2025 | Award | +98,866 | – | – | 120,711 |
| Peter J. Facchini CHIEF INNOVATION OFFICER | May 8, 2025 | Award | +24,717 | – | – | 33,058 |
| Kevin Michael Coveney CHIEF FINANCIAL OFFICER | May 8, 2025 | Award | +74,150 | – | – | 86,584 |
| Michael D. Webb Director | Oct 9, 2024 | Award | +47,733 | – | – | 47,733 |
| Kevin Michael Coveney CHIEF FINANCIAL OFFICER | Oct 9, 2024 | Award | +100,000 | – | – | 186,500 |
| Marcus Schabacker Director | Oct 9, 2024 | Award | +47,733 | – | – | 48,053 |
| George A. Kegler Director | Oct 9, 2024 | Award | +47,733 | – | – | 48,053 |
| Joseph Edward Tucker CHIEF EXECUTIVE OFFICER, Director | Oct 9, 2024 | Award | +161,633 | – | – | 335,829 |
| Peter J. Facchini CHIEF INNOVATION OFFICER | Oct 9, 2024 | Award | +40,000 | – | – | 130,856 |
| Frank Pasqualone Director | Oct 9, 2024 | Award | +47,733 | – | – | 48,733 |
| Sheila DeWitt Director | Oct 9, 2024 | Award | +27,845 | – | – | 27,845 |
| Peter J. Facchini CHIEF INNOVATION OFFICER | Feb 22, 2024 | Award | +50,000 | – | – | 90,856 |
| Kevin Michael Coveney CHIEF FINANCIAL OFFICER | Feb 22, 2024 | Award | +60,000 | – | – | 86,500 |
| Joseph Edward Tucker CHIEF EXECUTIVE OFFICER, Director | Feb 22, 2024 | Award | +100,000 | – | – | 174,196 |
| Frank Pasqualone Director | Sep 15, 2023 | Buy | +1,000 | $2.14 | $2.14K | 1,000 |
| Kevin Michael Coveney Chief Financial Officer | Mar 13, 2023 | Award | +26,500 | – | – | 26,500 |
| Peter J. Facchini Chief Innovation Officer | Jan 25, 2023 | Award | +17,000 | – | – | 40,865 |
| Joseph Edward Tucker Chief Executive Officer, Director | Jan 25, 2023 | Award | +44,000 | – | – | 74,196 |
| Jillian Marie Hagel Vice President of Innovation | Jan 25, 2023 | Award | +12,000 | – | – | 35,802 |
| Avani Kanubaddi President and COO | Jan 25, 2023 | Award | +10,000 | – | – | 48,346 |
| Joseph Edward Tucker Chief Executive Officer, Director | Oct 13, 2021 | Award | +1,374 | – | – | 15,196 |
| Joseph Edward Tucker Chief Executive Officer, Director | Oct 13, 2021 | Award | +15,000 | – | – | 30,196 |
| Peter J. Facchini Chief Scientific Officer | Oct 13, 2021 | Award | +1,021 | – | – | 13,356 |
| Peter J. Facchini Chief Scientific Officer | Oct 13, 2021 | Award | +10,500 | – | – | 23,856 |
| Jillian Marie Hagel Chief Technology Officer | Oct 13, 2021 | Award | +10,500 | – | – | 23,802 |
| Jillian Marie Hagel Chief Technology Officer | Oct 13, 2021 | Award | +1,021 | – | – | 13,302 |
| Jillian Marie Hagel Chief Technology Officer | Sep 16, 2021 | Award | +531,602 | – | – | 531,602 |
| Jillian Marie Hagel Chief Technology Officer | Sep 16, 2021 | Award | +82,398 | – | – | 82,398 |
| Peter J. Facchini Chief Scientific Officer | Sep 16, 2021 | Award | +531,602 | – | – | 531,602 |
| Peter J. Facchini Chief Scientific Officer | Sep 16, 2021 | Award | +85,056 | – | – | 85,056 |
| Joseph Edward Tucker Chief Executive Officer, Director | Sep 16, 2021 | Award | +691,083 | – | – | 691,083 |
| Joseph Edward Tucker Chief Executive Officer, Director | Sep 16, 2021 | Award | +691,083 | – | – | 691,083 |
| Douglas Lind Director | Mar 18, 2021 | Award | +2,265 | – | – | 2,265 |
| Buiten John Van Chief Financial Officer | Mar 4, 2021 | Award | +25,000 | – | – | 25,000 |
| Marcus Schabacker Director | Feb 15, 2021 | Award | +15,957 | – | – | 15,957 |
| Solomon Mayer Director | Feb 15, 2021 | Award | +15,957 | – | – | 15,957 |
| George A. Kegler Director | Feb 15, 2021 | Award | +15,957 | – | – | 15,957 |
| Brent Kelton Chief Executive Officer | Feb 5, 2019 | Other | +986,777 | – | – | 1,079,953 |
| Family 2008 Revocable Trust Dated 02/28/2008 Sikaria 10% owner | Nov 16, 2018 | Sale | −6,657 | $0.30 | $2.00K | 2,310,700 |
| Family 2008 Revocable Trust Dated 02/28/2008 Sikaria 10% owner | Nov 16, 2018 | Sale | −1,850 | $0.29 | $537 | 2,310,700 |
| Family 2008 Revocable Trust Dated 02/28/2008 Sikaria 10% owner | Nov 16, 2018 | Sale | −58,850 | $0.29 | $17.07K | 2,250,000 |
| Family 2008 Revocable Trust Dated 02/28/2008 Sikaria 10% owner | Nov 16, 2018 | Sale | −58 | $0.30 | $17 | 2,349,942 |
| Family 2008 Revocable Trust Dated 02/28/2008 Sikaria 10% owner | Nov 16, 2018 | Sale | −15,251 | $0.30 | $4.58K | 2,317,557 |
| Family 2008 Revocable Trust Dated 02/28/2008 Sikaria 10% owner | Nov 16, 2018 | Sale | −200 | $0.30 | $60 | 2,317,357 |
| Family 2008 Revocable Trust Dated 02/28/2008 Sikaria 10% owner | Nov 16, 2018 | Sale | −1,500 | $0.30 | $450 | 2,348,442 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short % of float
0.74%
0M shares short
Days to cover
1.0
At 0M shares a day
Change since last report
-49.3%
From 0M shares
Short volume, 20 days
30.8%
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Enveric Biosciences's stock actually held short. Settlement fails (shares not delivered on time) peaked at 13,071 shares on Oct 13, 2026 over the last 90 days.
See a number that looks wrong?